Korean J Gastroenterol.  2018 Sep;72(3):155-158. 10.4166/kjg.2018.72.3.155.

Multiple Pyoderma Gangrenosum in Ulcerative Colitis

• Kim SB
• Lee SH

• KMID: 2420755
• DOI: http://doi.org/10.4166/kjg.2018.72.3.155

Abstract

No abstract available.

MeSH Terms

Colitis, Ulcerative*
Pyoderma Gangrenosum*
Pyoderma*
Ulcer*

Figure

• 

  Fig. 1 Abdominal computed tomography scan showed wall thickening of sigmoid colon and rectum (white arrows).

• 

  Fig. 2 Colonoscopy showed diffuse hyperemic mucosa with aphthous ulcers and mucosal edema and hemorrhages at sigmoid colon (A) and multiple deep ulcers with exudate at the rectum (B).

• 

  Fig. 3 Rectum biopsy showed lymphoplasmacytic infiltration, ulceration, and a few distorted crypts (H&E, ×10).

• 

  Fig. 4 On admission day 2, the patient presented painful nodules and erythematous lesions on his right knee (A) and left foot (B) that progressed rapidly to irregular ulcers.

• 

  Fig. 5 Biopsy specimen from the ulcer of the right knee showed granulation tissue, lymphocyte infiltration, and abscess formation (H&E, ×100) (A) and abundant neutrophilic infiltration, resulting in abscess formation (H&E, ×200) (B).

• 

  Fig. 6 Incision and drainage of skin lesions of the left thumb (A), foot (B), and right knee (C) was performed.

• 

  Fig. 7 Healing ulcers with crust and hyperpigmentation on the left thumb (A), foot (B), and right knee (C) after systemic steroid therapy.

• 

  Fig. 8 Follow up sigmoidoscopy after treatment shows ulcer scar and pseudo-polyps at sigmoid colon and rectum.

Reference

1. Lee JI, Park HJ, Lee JY, Cho BK. A case of pyoderma gangrenosum with ulcerative colitis treated with mesalazine. Ann Dermatol. 2010; 22:422–425.

2. Binus AM, Qureshi AA, Li VW, Winterfield LS. Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients. Br J Dermatol. 2011; 165:1244–1250.

3. Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol. 1996; 34:395–409. quiz 410-412.

4. Mlika RB, Riahi I, Fenniche S, et al. Pyoderma gangrenosum: a report of 21 cases. Int J Dermatol. 2002; 41:65–68.

5. Greuter T, Navarini A, Vavricka SR. Skin manifestations of inflammatory bowel disease. Clin Rev Allergy Immunol. 2017; 53:413–427.

6. Ahn C, Negus D, Huang W. Pyoderma gangrenosum: a review of pathogenesis and treatment. Expert Rev Clin Immunol. 2018; 14:225–233.

7. Byeon YM, Lee J, Lee SJ, et al. Peritonsillar involvement in pyoderma gangrenosum associated with ulcerative colitis. Intest Res. 2014; 12:153–156.

8. Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2015; 21:1982–1992.

9. Herberger K, Dissemond J, Hohaus K, Schaller J, Anastasiadou Z, Augustin M. Treatment of pyoderma gangrenosum: retrospective multicentre analysis of 121 patients. Br J Dermatol. 2016; 175:1070–1072.

10. Ormerod AD, Thomas KS, Craig FE, et al. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ. 2015; 350:h2958.

11. Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006; 55:505–509.

12. Al Rajabi W, Venturini M, Sala R, Calzavara-Pinton P. Wegener's granulomatosis of the penis: genital presentation of systemic disease. Dermatology. 2006; 212:370–372.